TIDMAFRI
11 July 2018
AfriAg Global PLC
("AfriAg Global" or the "Company")
Update: Expansion of Investment Strategy to include Medical Cannabis
AfriAg Global PLC, the London listed global food and logistics investment
group, provides an update on its intention to seek shareholder approval to
expand its investment strategy to include investments in the developing markets
for medicinal cannabis derivatives, or related products.
David Lenigas, AfriAg Global's Chairman commented:
"The legalised global cannabis industry is a fast-growing sector with many
international governments now legalising the use of cannabis products for
medical use. Since out last announcement on this matter, the Company has
engaged experienced UK legal counsel as part of the process of gaining
approvals from our regulators to actively engage in this very exciting sector
and we now in active discussions with leading global experts in the medical
cannabis field to join our advisory board."
The Company's expanded investment strategy will include investments in
companies, projects or products that are either progressing medicinal cannabis
research and development; producing or cultivating medicinal cannabis; or
commercialising or marketing medicinal cannabis and its derivatives. AfriAg
will look to invest in companies and projects in jurisdictions which have
well-developed and reputable laws and regulation for the research and
production of medicinal cannabis and in jurisdictions that are signatories to
the United Nation's conventions on narcotics.
The Company is likely to be an active investor within this sector and acquire
control of certain target companies although it may also consider acquiring
non-controlling shareholdings. The proposed investments to be made by the
Company may be in either quoted or unquoted securities and made by direct
acquisition of an interest in companies, partnerships or joint ventures, or
direct interests in projects and can be at any stage of development.
Accordingly, the Company's equity interest in a proposed investment may range
from a minority position to 100 per cent. ownership and a controlling interest.
The Directors primary objective is to achieve the best possible value over time
for Shareholders, primarily through capital growth.
The Board believes that their collective experience, together with their
extensive network of contacts, will assist them in the identification,
evaluation and funding of appropriate investment opportunities within the
medicinal cannabis space. When necessary, other external professionals will be
engaged to assist in the due diligence on prospective targets and their
management teams. The Directors will also consider appointing additional
directors and /or advisors with relevant experience if the need arises.
There will be no limit on the number of projects into which the Company may
invest within this space, and the Company may invest in a number of
propositions or in just one investment, which may be deemed to be a reverse
takeover pursuant to Rule 58 of the NEX Exchange Rules. The Company may need to
raise additional funds for these purposes and may use both debt and/or equity.
It is anticipated that there may be opportunities to spin out businesses
privately or via IPO where Shareholders may be able to benefit via
distributions of cash and/or shares and/or rights to subscribe in listings. It
is anticipated that the Company will hold investments for the medium to long
term, although where opportunities exist for shorter term gains the Company may
take advantage of such opportunities.
If the Company takes a controlling stake, the acquisition could trigger a
Reverse Takeover under Rule 57 of the NEX Exchange Rules.
The directors of the Company accept responsibility for the contents of this
announcement.
-ENDS-
Afriag Global Plc +44 (0)20 7440 0640
David Lenigas (Executive Chairman)
Peterhouse Capital Limited +44 (0)20 7469 0930
Guy Miller
Fungai Ndoro
Notes to Editors:
The Company's global distribution footprint has expanded considerably over the
years, moving and distributing perishable food products by road, air and sea
for many blue-chip companies around the globe.
AfriAg Global's 100% owned subsidiary, AfriAg Marketing recorded revenues of GBP
3.122 million for 2017, with its 40% owned agri-logistics group AfriAg (Pty)
Limited adding value with its full year revenues growing to GBP14.746 million.
AfriAg Global's current Investment Strategy:
AfriAg Global Plc, formerly AfriAg plc, was re-classified as an Investing
Company and the following investing strategy has been approved by shareholders:
The Directors intend to seek to acquire a direct and/or an indirect interest in
businesses involved in agriculture generally and the production, processing,
logistics and distribution of agricultural produce.
The Company will initially focus on opportunities in Europe, Africa and the
Middle East but will consider possible opportunities anywhere in the world.
The Company may invest by way of purchasing quoted shares in appropriate
companies, outright acquisition or by the acquisition of assets, including the
intellectual property, of a relevant business, or by entering into partnerships
or joint venture arrangements. Such investments may result in the Company
acquiring the whole or part of a company (which in the case of an investment in
a company may be private or listed on a stock exchange, and which may be
pre-revenue), and such investments may constitute a minority stake in the
company, partnership and/or joint venture in question. The Company will not
have a separate investment manager.
The Company may be both an active and a passive investor depending on the
nature of the individual investments. Although the Company intends to be a
medium to long-term investor, the Directors will place no minimum or maximum
limit on the length of time that any investment may be held and therefore
shorter term disposal of any investments cannot be ruled out.
There will be no limit on the number of businesses into which the Company may
invest, and the Company's financial resources may be invested in a number of
propositions or in just one investment.
Investments may be in all types of assets and there will be no investment
restrictions. The Company will require additional funding as investments are
made and new opportunities arise. The Directors may offer new Ordinary Shares
by way of consideration as well as cash, thereby helping to preserve the
Company's cash resources for working capital. The Company may in appropriate
circumstances, issue debt securities or otherwise borrow money to complete an
investment. The Directors do not intend to acquire any cross-holdings in other
corporate entities that have an interest in the Ordinary Shares.
END

You're now leaving this website!

You are now leaving the NEX Exchange web-site. NEX Exchange accepts no responsibility for the content of the website you are about to access or for any reliance placed by you or any person on the information contained on it.

By allowing this link NEX Exchange does not intend to solicit business or offer any securities to any person in any country, whether directly or indirectly.

The Reports available to download on nexexchange.com are produced by independent third parties and are for distribution only under such circumstances as may be permitted by such third parties and applicable law.
They are published solely for informational purposes and should not be construed as a recommendation to sell, buy or hold any product, investment, security or any other financial instrument. Any opinion, view
or idea contained in any Report is the author’s own and does not reflect or represent the opinions, views or ideas of NEX Group plc (“NEX Exchange”), nor any of its affiliates, directors,
officers, employees or agents. Publication of the Reports does not signify endorsement by NEX Exchange of any of the information contained therein. NEX Exchange is not involved in the preparation of any of the Reports and does
not make any representation or warranty, express or implied, as to the accuracy, completeness, suitability or correctness of any of the information presented by individual authors in the Reports. Neither NEX Exchange,
nor any of its affiliates, directors, officers, employees or agents, accepts any liability for any loss or damage, howsoever caused, arising from any reliance on any information or views contained in the Reports.
Any opinions expressed in the Reports are subject to change without notice and are not to be relied upon as investment advice, which should be sought from your independent advisers. NEX Exchange is under no obligation to
update or keep current the information contained in the Reports. Please refer to NEX Exchange’s Terms of Use for further information.